CL2015000259A1 - Composicion para formar un implante intramuscular in situ que comprende un polimero termoplastico biodegradable de acido polilactico (pla), dimetilsulfoxido (dmso) y un compuesto derivado de 1-ilmetil-bencil-1,2,4-triazol, inhibidor de aromatasa; kit para la formacion in situ de la composicion; y su uso para tratar el cancer. - Google Patents

Composicion para formar un implante intramuscular in situ que comprende un polimero termoplastico biodegradable de acido polilactico (pla), dimetilsulfoxido (dmso) y un compuesto derivado de 1-ilmetil-bencil-1,2,4-triazol, inhibidor de aromatasa; kit para la formacion in situ de la composicion; y su uso para tratar el cancer.

Info

Publication number
CL2015000259A1
CL2015000259A1 CL2015000259A CL2015000259A CL2015000259A1 CL 2015000259 A1 CL2015000259 A1 CL 2015000259A1 CL 2015000259 A CL2015000259 A CL 2015000259A CL 2015000259 A CL2015000259 A CL 2015000259A CL 2015000259 A1 CL2015000259 A1 CL 2015000259A1
Authority
CL
Chile
Prior art keywords
situ
composition
ylmethyl
pla
dimethylsulfoxide
Prior art date
Application number
CL2015000259A
Other languages
English (en)
Spanish (es)
Inventor
Rodriguez Guillermo Franco
Aduriz Ibon Gutierro
Original Assignee
Farmacéuticos Rovi S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000259(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmacéuticos Rovi S A Lab filed Critical Farmacéuticos Rovi S A Lab
Publication of CL2015000259A1 publication Critical patent/CL2015000259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015000259A 2012-08-03 2015-02-03 Composicion para formar un implante intramuscular in situ que comprende un polimero termoplastico biodegradable de acido polilactico (pla), dimetilsulfoxido (dmso) y un compuesto derivado de 1-ilmetil-bencil-1,2,4-triazol, inhibidor de aromatasa; kit para la formacion in situ de la composicion; y su uso para tratar el cancer. CL2015000259A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231271A ES2390439B1 (es) 2012-08-03 2012-08-03 Composición inyectable

Publications (1)

Publication Number Publication Date
CL2015000259A1 true CL2015000259A1 (es) 2015-06-05

Family

ID=47046938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000259A CL2015000259A1 (es) 2012-08-03 2015-02-03 Composicion para formar un implante intramuscular in situ que comprende un polimero termoplastico biodegradable de acido polilactico (pla), dimetilsulfoxido (dmso) y un compuesto derivado de 1-ilmetil-bencil-1,2,4-triazol, inhibidor de aromatasa; kit para la formacion in situ de la composicion; y su uso para tratar el cancer.

Country Status (31)

Country Link
EP (1) EP2879661B1 (enExample)
JP (1) JP6317348B2 (enExample)
KR (1) KR101892109B1 (enExample)
CN (1) CN104519870B (enExample)
AU (1) AU2013298705B2 (enExample)
BR (1) BR112015002370B1 (enExample)
CA (1) CA2880347C (enExample)
CL (1) CL2015000259A1 (enExample)
CY (1) CY1125157T1 (enExample)
DK (1) DK2879661T3 (enExample)
EA (1) EA033316B1 (enExample)
ES (2) ES2390439B1 (enExample)
HR (1) HRP20220537T1 (enExample)
HU (1) HUE058322T2 (enExample)
IL (1) IL236981B (enExample)
IN (1) IN2015DN01711A (enExample)
LT (1) LT2879661T (enExample)
MA (1) MA37870B1 (enExample)
MX (1) MX362874B (enExample)
MY (1) MY194726A (enExample)
NZ (1) NZ705558A (enExample)
PH (1) PH12015500231A1 (enExample)
PL (1) PL2879661T3 (enExample)
PT (1) PT2879661T (enExample)
RS (1) RS63104B1 (enExample)
SG (1) SG11201500793VA (enExample)
SI (1) SI2879661T1 (enExample)
SM (1) SMT202200127T1 (enExample)
UA (1) UA113317C2 (enExample)
WO (1) WO2014019972A1 (enExample)
ZA (1) ZA201501426B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CA3157003A1 (en) * 2019-10-07 2021-04-15 Oak Crest Institute Of Science Orally implantable drug delivery device
KR102319352B1 (ko) 2021-02-03 2021-10-29 바이오메디팜 어업회사법인 주식회사 첨연어의 수컷화 비율을 높이는 비호르몬적 방법
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2025153747A1 (es) * 2024-01-17 2025-07-24 Laboratorios Farmacéuticos Rovi, S.A. Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CA2665105A1 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and its' process of preparation
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
HRP20211853T1 (hr) * 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
AU2011336896B2 (en) 2010-11-24 2015-12-24 Durect Corporation Biodegradable drug delivery composition

Also Published As

Publication number Publication date
EA033316B1 (ru) 2019-09-30
IN2015DN01711A (enExample) 2015-05-22
MY194726A (en) 2022-12-15
IL236981A0 (en) 2015-03-31
JP6317348B2 (ja) 2018-04-25
WO2014019972A1 (en) 2014-02-06
MX2015001513A (es) 2015-04-08
ZA201501426B (en) 2016-01-27
ES2390439B1 (es) 2013-09-27
SI2879661T1 (sl) 2022-07-29
KR20150040337A (ko) 2015-04-14
MA37870B1 (fr) 2017-01-31
BR112015002370A2 (pt) 2017-07-04
SMT202200127T1 (it) 2022-07-21
JP2015523405A (ja) 2015-08-13
CA2880347C (en) 2021-05-04
CN104519870A (zh) 2015-04-15
HK1204551A1 (en) 2015-11-27
MA37870A1 (fr) 2016-04-29
PH12015500231B1 (en) 2015-04-06
EP2879661B1 (en) 2022-01-26
BR112015002370B1 (pt) 2023-04-25
SG11201500793VA (en) 2015-02-27
IL236981B (en) 2021-12-01
PH12015500231A1 (en) 2015-04-06
NZ705558A (en) 2018-02-23
AU2013298705B2 (en) 2018-03-08
PL2879661T3 (pl) 2022-05-16
AU2013298705A1 (en) 2015-03-12
EP2879661A1 (en) 2015-06-10
ES2926715T3 (es) 2022-10-27
MX362874B (es) 2019-02-20
HUE058322T2 (hu) 2022-07-28
HRP20220537T1 (hr) 2022-06-10
CN104519870B (zh) 2017-09-15
ES2390439A1 (es) 2012-11-13
DK2879661T3 (da) 2022-04-19
PT2879661T (pt) 2022-04-06
CY1125157T1 (el) 2024-02-16
EA201500196A1 (ru) 2015-05-29
RS63104B1 (sr) 2022-04-29
LT2879661T (lt) 2022-04-11
CA2880347A1 (en) 2014-02-06
KR101892109B1 (ko) 2018-09-28
UA113317C2 (xx) 2017-01-10

Similar Documents

Publication Publication Date Title
CL2015000259A1 (es) Composicion para formar un implante intramuscular in situ que comprende un polimero termoplastico biodegradable de acido polilactico (pla), dimetilsulfoxido (dmso) y un compuesto derivado de 1-ilmetil-bencil-1,2,4-triazol, inhibidor de aromatasa; kit para la formacion in situ de la composicion; y su uso para tratar el cancer.
CL2012002225A1 (es) Metodo para el tratamiento de una disfuncion de neurotransmision y otros estados asociados con la actividad de mglur4en que comprende el uso de compuestos heterociclicos derivados de pirazol condensado con otro heterociclo; compuestos; composiciones que los comprenden y el uso en el tratamiento de una disfuncion neurologica.
BR112014028755A2 (pt) composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112012010958A2 (pt) método para intensificação de feixe
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
CL2013002446A1 (es) Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer.
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CL2012000316A1 (es) Compuestos fungicidas derivados de n1-acil-5-fluoro-pirimidinona; composiciones que los comprenden y metodo que los emplea para combatir hongos fitopatogenos.
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
BR112012010170A2 (pt) composições de revestimento para desintegração/dissolução rápida
EA201400937A1 (ru) Способ получения 2-(2,3-диметилфенил)-1-пропаналя
BRPI0912251A2 (pt) aço de elevadas características para peças maciças.
BRPI1015559A2 (pt) forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação.
CL2014000595A1 (es) Extracto de cynara; composicion farmaceutica que lo contiene; y su uso para el tratamiento de hiperglucemia, hipercolesterolemia, hipertension y esteatosis hepatica.
BR112014021586A2 (pt) composição, processo para uma proteção de um material orgânico, e, uso de um composto
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
DOP2012000110A (es) Mezclas basadas en poliol para cemento hidraulico
ES1070960Y (es) Armario de proteccion para maquinas recreativas
ES1065081Y (es) Puntera de refuerzo para calzados de seguridad.
BRPI0919025A2 (pt) composto para eliminação local de tumores
ES1066998Y (es) Piezas modulares para la formacion de objetos desmontables
ES1072768Y (es) Maquina para la instalacion y desinstalacion de bombas en pozos.